331 related articles for article (PubMed ID: 28033288)
1. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma.
Li Z; Li N; Li F; Zhou Z; Sang J; Chen Y; Han Q; Lv Y; Liu Z
Medicine (Baltimore); 2016 Dec; 95(52):e5749. PubMed ID: 28033288
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of immune checkpoint proteins PD-1 and TIM-3 are associated with survival of patients with hepatitis B virus-related hepatocellular carcinoma.
Li Z; Li N; Li F; Zhou Z; Sang J; Jin Z; Liu H; Han Q; Lv Y; Liu Z
Oncotarget; 2016 May; 7(18):26168-80. PubMed ID: 27034168
[TBL] [Abstract][Full Text] [Related]
3. Genetic variations of PD1 and TIM3 are differentially and interactively associated with the development of cirrhosis and HCC in patients with chronic HBV infection.
Li Z; Li N; Zhu Q; Zhang G; Han Q; Zhang P; Xun M; Wang Y; Zeng X; Yang C; Liu Z
Infect Genet Evol; 2013 Mar; 14():240-6. PubMed ID: 23291409
[TBL] [Abstract][Full Text] [Related]
4. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
5. TIM3 gene polymorphisms in patients with chronic hepatitis B virus infection: impact on disease susceptibility and hepatocellular carcinoma traits.
Li Z; Liu Z; Zhang G; Han Q; Li N; Zhu Q; Lv Y; Chen J; Xing F; Wang Y; Li F
Tissue Antigens; 2012 Aug; 80(2):151-7. PubMed ID: 22587604
[TBL] [Abstract][Full Text] [Related]
6. Genetic association and interaction of PD1 and TIM3 polymorphisms in susceptibility of chronic hepatitis B virus infection and hepatocarcinogenesis.
Li F; Fan X; Wang X; Deng H; Zhang X; Zhang K; Li N; Han Q; Lv Y; Liu Z
Discov Med; 2019 Feb; 27(147):79-92. PubMed ID: 30939292
[TBL] [Abstract][Full Text] [Related]
7. PD-1 mRNA expression is associated with clinical and viral profile and PD1 3'-untranslated region polymorphism in patients with chronic HBV infection.
Zhang G; Li N; Zhang P; Li F; Yang C; Zhu Q; Han Q; Lv Y; Zhou Z; Liu Z
Immunol Lett; 2014 Nov; 162(1 Pt A):212-6. PubMed ID: 25218665
[TBL] [Abstract][Full Text] [Related]
8. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
9. Splenic CD4
Huang N; Zhou R; Chen H; Zhang S; Li J; Wei W; Sun J; Ren S; Li B; Deng H; Yang J; Ji F; Li Z
Int J Immunopathol Pharmacol; 2021; 35():20587384211061051. PubMed ID: 34930041
[No Abstract] [Full Text] [Related]
10. Genetic variants of programmed cell death 1 are associated with HBV infection and liver disease progression.
Hoan NX; Huyen PTM; Binh MT; Trung NT; Giang DP; Linh BT; Dung DTN; Pallerla SR; Kremsner PG; Velavan TP; Bang MH; Song LH
Sci Rep; 2021 Apr; 11(1):7772. PubMed ID: 33833369
[TBL] [Abstract][Full Text] [Related]
11. Tim-3 expression and its role in hepatocellular carcinoma.
Liu F; Liu Y; Chen Z
J Hematol Oncol; 2018 Oct; 11(1):126. PubMed ID: 30309387
[TBL] [Abstract][Full Text] [Related]
12. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.
Li H; Wu K; Tao K; Chen L; Zheng Q; Lu X; Liu J; Shi L; Liu C; Wang G; Zou W
Hepatology; 2012 Oct; 56(4):1342-51. PubMed ID: 22505239
[TBL] [Abstract][Full Text] [Related]
13. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma.
Kim KJ; Lee HW; Seong J
J Gastroenterol Hepatol; 2021 May; 36(5):1357-1365. PubMed ID: 33217056
[TBL] [Abstract][Full Text] [Related]
15. microRNA-4717 differentially interacts with its polymorphic target in the PD1 3' untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases.
Zhang G; Li N; Li Z; Zhu Q; Li F; Yang C; Han Q; Lv Y; Zhou Z; Liu Z
Oncotarget; 2015 Aug; 6(22):18933-44. PubMed ID: 25895129
[TBL] [Abstract][Full Text] [Related]
16. Association of T-cell immunoglobulin and mucin domain-containing molecule 3 (Tim-3) polymorphisms with susceptibility and disease progression of HBV infection.
Liao J; Zhang Q; Liao Y; Cai B; Chen J; Li L; Wang L
PLoS One; 2014; 9(5):e98280. PubMed ID: 24867713
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes.
Zahran AM; Hetta HF; Rayan A; Eldin AS; Hassan EA; Fakhry H; Soliman A; El-Badawy O
Cancer Immunol Immunother; 2020 Jul; 69(7):1253-1263. PubMed ID: 32170378
[TBL] [Abstract][Full Text] [Related]
18. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
19. Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma.
Sun R; Li J; Lin X; Yang Y; Liu B; Lan T; Xiao S; Deng A; Yin Z; Xu Y; Xiang Z; Wu B
Front Immunol; 2023; 14():1079495. PubMed ID: 37077908
[TBL] [Abstract][Full Text] [Related]
20. Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors.
Lu JC; Zeng HY; Sun QM; Meng QN; Huang XY; Zhang PF; Yang X; Peng R; Gao C; Wei CY; Shen YH; Cai JB; Dong RZ; Shi YH; Sun HC; Shi YG; Zhou J; Fan J; Ke AW; Yang LX; Shi GM
Theranostics; 2019; 9(16):4678-4687. PubMed ID: 31367249
[No Abstract] [Full Text] [Related]
[Next] [New Search]
